Compare D Wave Quantum Inc (QBTS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Sanofi SA — how do they compare? D Wave Quantum Inc trades at $17.18 (market cap $6.38B), while Sanofi SA trades at $43.12 (market cap $103.41B). The key difference: Sanofi SA is far larger — about 16.2× D Wave Quantum Inc's market cap, and Sanofi SA pays a 5.65% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| QBTS | SNY | |
|---|---|---|
Market Cap | $6.38B | $103.41B |
Sector | Technology | Health |
52-Week High | $44.78 | $52.34 |
52-Week Low | $12.98 | $41.33 |
Enterprise Value | $5.88B | $123.44B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $17.67, down 33% year-to-date, with a bearish technical signal and negative profitability metrics including a net income margin of -2,001.59% for 2026. Recent news highlights a $100 million U.S. government funding injection via the CHIPS Act, boosting sentiment amid ongoing losses and legal investigations.
The stock faces high risk from persistent losses and lofty valuations but holds long-term potential in quantum computing, supported by unanimous analyst buy ratings and a $37.00 consensus price target. Investors must weigh government backing against cash burn and competitive pressures in a nascent industry.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
